

# Nuclear Medicine, a dynamic industry

*The nuclear medicine industry has been very active in the recent months, confirming an increasing interest from investors and the pharmaceutical industrie*

LOUVAIN-LA-NEUVE AND LALAYE, BELGIUM AND FRANCE, March 23, 2016 /EINPresswire.com/ -- The [nuclear medicine](#) industry has been very active in the recent months which can be highlighted through several key events, confirming the trend announced by MEDraysintell since two years which anticipated an increasing interest from investors and conventional pharmaceutical industries for the nuclear medicine market, mainly in the therapeutic area.

During the month of March 2016, ITM (Isotopen Technologien München) successfully raised EUR 20 million to fund the development of its promising proprietary pipeline of Targeted Radionuclide Therapies, Clarity Pharmaceuticals, an early stage Australian company, has been awarded AU\$ 1 million to fund a definitive clinical trial of Cu-64 SARTATE, a neuroendocrine tumors imaging radiopharmaceutical and the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study started to enroll as many as 18,000 patients to determine the clinical usefulness on patient-oriented outcomes of a brain positron emission tomography (PET) scan, using new fluorinated tracers and IBA successfully completed the sale of IBA Molecular to funds advised by

CapVest Partners LP.

In February 2016, inviCRO acquired Molecular NeuroImaging, a company specializing in the application of radiolabeled biomarkers, Ipsen and 3B Pharmaceuticals signed a license agreement to develop novel radiopharmaceuticals, and Bayer published once again strong results for its Xofigo (radium-223 dichloride), a radiotherapeutic used in the treatment of prostate and bone cancers, with sales rising by over 60% in 2015 versus 2014. Last year, the French company Ipsen had already acquired Octreopharm, a German company specialized in the development of radiopharmaceuticals, hence confirming its interest in this area.

In January 2016, IBA Molecular North America, a manufacturer and distributor of radiopharmaceuticals, was renamed Zevacor Pharma, Inc., following the acquisition made by mid-2015, and Advanced Accelerator Applications SA acquired the IDB Group, The Netherlands, a producer of Lutetium 177.

By end of 2015, FACIT invested in Fusion Pharmaceuticals to support the development of alpha particle-emitting radiotherapeutics.

The global nuclear medicine industry is evaluated in a MEDraysintell's report and directory, providing in a 930-page document a complete description of over 335 radiopharmaceuticals and radionuclides and more than 160 companies and institutions active in this field around the world.



*Bringing value to businesses and investors*

**Strategic intelligence for  
the radiation healthcare**

*A series of expert market reports  
and directories*

**Nuclear Medicine**  
**Cyclotrons**  
**Proton Therapy**  
**Brachytherapy**

[www.medraysintell.com](http://www.medraysintell.com)

[http://medraysintell.com/Nuclear\\_Medicine.html](http://medraysintell.com/Nuclear_Medicine.html)

Furthermore, our recent reports on [Brachytherapy](#) and [Cyclotrons](#) are showing as well the contribution of these technologies to the rising interests for nuclear medicine industry.

Detailed table of contents and sample pages of our reports are available upon request.

About MEDraysintell

Strategic intelligence for the radiation healthcare

Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy.

We offer the most comprehensive set of reports and directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories.

MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. [www.medraysintell.com](http://www.medraysintell.com)

Paul-Emmanuel Goethals and Richard Zimmermann

MEDraysintell

+32 491 080 968 and +33 6 82 80 06 00

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.